1stOncology™: Cancer Intelligence Service – Page 13313 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Atara Biotherapeutics to Participate in Citi 14th Annual Biotech Conference

On August 28, 2019 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, reported that Pascal Touchon, the Company’s President and Chief Executive Officer, will participate in a panel titled "Up and Comers in the Cell Therapy Space" at Citi 14th Annual Biotech Conference on Wednesday, September 4, 2019 at 1:30 p.m. EDT (Press release, Atara Biotherapeutics, AUG 28, 2019, View Source [SID1234539102]). The conference will be held at the Four Seasons Hotel in Boston, MA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A live audio webcast of the panel will be available by visiting the Investors and Media section of the Atara website. An archived replay of the webcast will be available on the Company’s website for 14 days following the live panel.

ORIC to Participate in Citi’s 14th Annual Biotech Investor Conference

On August 28, 2019 ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing cancer treatments that address mechanisms of therapeutic resistance, reported that it will be participating in Citi’s 14th Annual Biotech Conference in Boston (Press release, ORIC Pharmaceuticals, AUG 28, 2019, View Source [SID1234539100]). On Wednesday, September 4, 2019 at 3:45 pm ET, Jacob Chacko, MD, Chief Executive Officer, will participate in a panel discussion entitled, "Emerging Innovators – An Introduction to Biotech Privates."

Harmonic Bionics Announces Appointment of Christopher Prentice as Chief Executive Officer

On August 28, 2019 Harmonic Bionics, Inc. reported that Christopher Prentice has been appointed Chief Executive Officer and member of the Harmonic Bionics Board of Directors effective immediately (Press release, Harmonics, AUG 28, 2019, View Source [SID1234539099]). Mr. Prentice succeeds Youngmok Yun, who is a co-founder of the company and who will remain in the role of Chief Technology Officer/Chief Operating Officer.

"As Harmonic Bionics prepares for the commercialization of robotic upper extremity rehabilitation system, we sought a leader who had direct experience in helping early stage robotic companies achieve their goals," said Yun. "Chris is an outstanding choice to lead the company into the market." Mr. Prentice said, "Harmonic Bionics has a brilliant product development team and an innovative system that can advance the field of neurorehabilitation. Based on my experience and knowledge of the commercialization of robotic systems, gained at both Intuitive and Mazor, I am very excited about the opportunity at Harmonic Bionics and I am honored to join the team."

Christopher Prentice has over 20 years of medical device experience in both large strategic healthcare companies and in successful startup companies. Most recently he was Vice President of Commercial Integration at Medtronic. Prior to his position at Medtronic, he was CEO of Mazor Robotics, Inc. and Chief Commercial Officer of Mazor Robotics Ltd., companies that were acquired by Medtronic in December 2018. Prior to joining Mazor Robotics in 2010, he worked in finance at Tampa General Hospital and held sales positions at Intuitive Surgical. Chris started his career in the medical device industry in sales, marketing, and product management positions at Johnson & Johnson. He holds an undergraduate in engineering from the United States Military Academy at West Point and graduate degrees from Western New England University and the University of South Florida.

Arena Pharmaceuticals to Participate in Upcoming Investor Conferences

On August 28, 2019 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported that members of its senior management team will participate in the upcoming investor conferences (Press release, Arena Pharmaceuticals, AUG 28, 2019, View Source [SID1234539098]):

Wells Fargo Global Healthcare Conference – Presenting on Wednesday, September 4, at 8:30 AM EDT in Boston
Citi Biotech Conference – Hosting investor meetings on Thursday, September 5, in Boston
A live audio webcast of the Wells Fargo presentation will be available under the investor relations section of Arena’s website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the events.

BioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York

On August 28, 2019 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) reported that Dan Spiegelman, Executive Vice President and Chief Financial Officer, will present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 at 8:35am ET in New York (Press release, BioMarin, AUG 28, 2019, View Source [SID1234539097]). To access the live webcast, please visit the investor section of the BioMarin website, www.biomarin.com. A replay will also be archived on the site for at least one week following each event.